HR+/HER2- EARLY BREAST CANCER
Clinical trials for HR+/HER2- EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Coaching may boost cancer pill adherence in new study
Disease control Not yet recruitingThis study looks at whether extra education and counseling helps women with HR+/HER2- early breast cancer take their prescribed medication, abemaciclib, more consistently. About 257 women will either receive standard care or additional coaching. The main goal is to see if coachin…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Phase: NA • Sponsor: Institut fuer Frauengesundheit • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New study could spare some breast cancer patients from chemo
Disease control Not yet recruitingThis study looks at whether a combination of ribociclib (a targeted drug) and hormone therapy can be as effective as chemotherapy followed by the same combo for people with a common type of early breast cancer (HR+/HER2-). Only patients whose blood tests show no signs of cancer D…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Blood test catches cancer early; drug aims to stop return
Disease control Not yet recruitingThis study tests whether monitoring tumor DNA in the blood (ctDNA) and treating with abemaciclib can prevent breast cancer from coming back. 30 people with HR+/HER2- breast cancer who have finished standard treatment will be followed. If ctDNA is detected, they will receive abema…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Nagoya City University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC